Vivimed Labs seeks 3-month extension for FY26 AGM

What Vivimed Labs disclosed to exchanges

Vivimed Labs Limited has sought more time to convene its Annual General Meeting (AGM) for FY26. The company’s Committee of Creditors (CoC) approved an application to the Registrar of Companies (RoC), Bangalore, seeking a three-month extension. The decision was communicated to the stock exchanges through a regulatory filing.

The company filed the update with BSE and NSE on September 26, 2026. The approval itself was taken through a resolution passed by circulation on September 25, 2026. The application requests additional time from the office of the RoC in Karnataka to hold the shareholder meeting.

CoC approval and the resolution by circulation

According to the disclosure, the approval was granted by the Members of the Committee of Creditors via a Resolution by Circulation. This indicates the decision was taken without a physical meeting, using the circulation process referenced in the filing. The matter relates to statutory meeting timelines, and the company positioned it as a compliance-driven step.

The intimation to stock exchanges was signed by the company secretary, Yugandhar Kopparthi. The filing frames the extension request as procedural, aimed at meeting statutory requirements while accommodating scheduling constraints for the AGM.

What the extension request covers

The request is specific: a three-month extension to convene the AGM for FY26. The filing identifies the approving body as the CoC and the destination regulator as the RoC, Bangalore, under Karnataka. The company did not disclose the revised AGM date in the text provided.

By seeking an extension from the RoC, the company is using the formal route typically adopted when companies are unable to meet the standard AGM timelines. The filing does not provide additional reasons beyond scheduling constraints.

Key dates and filed details

Vivimed Labs’ filing provides clear timestamps for the approval and disclosure. The resolution date is September 25, 2026, and the exchange filing date is September 26, 2026. The action is described as an application for AGM extension, with FY26 as the fiscal year concerned.

Summary of disclosed facts

CIRP context around governance and creditor oversight

The same set of disclosures also places Vivimed Labs within the Corporate Insolvency Resolution Process (CIRP) framework. The text references an NCLT order dated April 15, 2026 as the CIRP trigger. It also states that the board’s powers are suspended from April 15, 2026, highlighting why creditor-led processes like CoC approvals matter for company actions.

In this context, approvals and procedural applications are being routed through the CoC mechanism. The exchange updates cited in the material also show the company has been regularly intimating markets about CoC milestones.

Committee of Creditors meetings mentioned in disclosures

Beyond the AGM extension item, the content references multiple CoC meetings scheduled during the CIRP period. It mentions the first CoC meeting on May 13, 2026, the sixth CoC meeting scheduled on August 18, 2026 (to be held through audio-visual means), and another CoC meeting scheduled for September 10, 2026.

The September 10 meeting is described as being conducted through audio-visual means and as part of the CIRP. The notice for the September meeting is stated to have been signed by T Narayana Swamy, the interim resolution professional, and linked to the April 15, 2026 NCLT order.

CIRP milestones referenced

Market snapshots included in the material

The provided text includes a market price reference: as of September 23, 2026, Vivimed Labs’ share price is stated as ₹5.3. The material also notes that there are no upcoming board meetings listed under the “BOARD MEETING” section.

Separately, the content states “The next results date for Vivimed Labs Ltd is 17 July 2026.” This is presented as part of the feed-style information and is included here as disclosed, without additional interpretation.

Why the AGM extension matters for investors

An AGM extension request is primarily a compliance and governance event rather than an operational update. In Vivimed Labs’ case, the filing explicitly ties the approval mechanism to the CoC, which aligns with the broader CIRP framework referenced across the disclosures. For shareholders tracking statutory filings, the extension request signals that the company is formally seeking more time to complete the FY26 AGM process.

At the same time, the series of CoC meeting intimations indicates that creditor processes remain active and are being communicated to exchanges through scheduled meetings and procedural steps. The filing does not claim any immediate operational change linked to the AGM extension request.

What to watch next

The immediate next step is the RoC’s consideration of the company’s application for additional time to convene the FY26 AGM. On the CIRP side, the disclosures referenced in the material place another CoC meeting on the calendar for September 10, 2026.

For investors, upcoming exchange filings may clarify whether the requested AGM extension is granted and whether the company sets a revised AGM schedule after RoC communication.